Table 3 Characteristics of respondents (n=80) stratified by site
From: Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
| All | China | Japan | South Korea | Taiwan | p-value | |
|---|---|---|---|---|---|---|
| Primary Role, % | ||||||
| Clinicians | 60.0 | 15.0 | 15.0 | 15.0 | 15.0 | 0.196 |
| Hepatologist | 18.8 | 2.5 | 5.0 | 7.5 | 3.8 | |
| Oncologist | 21.3 | 10.0 | 2.5 | 1.3 | 7.5 | |
| Radiologist | 3.8 | 1.3 | 1.3 | 1.3 | 0.0 | |
| Surgeon | 12.5 | 0.0 | 8.3 | 4.2 | 0.0 | |
| Other | 3.8 | 0.4 | 1.1 | 1.1 | 1.1 | |
| Policy makers | 25.0 | 6.3 | 6.3 | 6.3 | 6.3 | 0.167 |
| Governmental | 18.8 | 5.0 | 6.3 | 5.0 | 2.5 | |
| Non-Governmental | 6.3 | 1.3 | 0.0 | 1.3 | 3.8 | |
| Advocates | 15.0 | 3.8 | 3.8 | 3.8 | 3.8 | 0.518 |
| Disease advocacy | 5.0 | 0.0 | 1.3 | 1.3 | 2.5 | |
| Media/Spokesperson | 3.8 | 1.3 | 1.3 | 0.0 | 1.3 | |
| Patient advocacy | 6.3 | 2.5 | 1.3 | 2.5 | 0.0 | |
| Area of Involvement, % | 0.002** | |||||
| Hepatitis | 26.3 | 5.0 | 11.3 | 3.8 | 6.3 | |
| HCC | 57.5 | 17.5 | 13.7 | 16.3 | 10.0 | |
| Metastatic liver cancer | 10.0 | 2.5 | 0.0 | 0.0 | 7.5 | |
| Transplantation | 6.3 | 0.0 | 0.0 | 5.0 | 1.3 | |
| Level of Involvement, % | 0.029* | |||||
| International | 15.0 | 3.8 | 3.8 | 5.0 | 2.5 | |
| Local/municipality | 6.3 | 5.0 | 0.0 | 1.3 | 0.0 | |
| National | 56.3 | 13.7 | 11.3 | 17.5 | 13.7 | |
| Regional/provincial | 22.5 | 2.5 | 10.0 | 1.3 | 8.8 | |
